Lysogene MPS IIIA parent advisory board holds inuagural meeting. Each member is a parent of a child with #Sanfilippo and will help the company establish realistic expectations for therapies, hear about clinical trial design and recruitment effort and reiterate the importance of addressing the cognitive problems of those affected by MPS IIIA.
“Lysogene is dedicated to placing the patient at the center of the clinical trial design, and feedback from the Parent Advisory Board will be a tremendous addition to our efforts,” said Samantha Parker, Lysogene’s chief patient access officer. “The value of the meeting was beyond our expectations, and we thank the families for their candid input. We intend to use the valuable feedback in the design of our pivotal clinical trial in MPS IIIA.”